Literature DB >> 2897238

cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.

P J Kuppen1, H Schuitemaker, L J van 't Veer, E A de Bruijn, A T van Oosterom, P I Schrier.   

Abstract

In two human ovarian tumor cell lines, resistance to cis-diamminedichloroplatinum(II) (CDDP) was induced by continuous exposure of the parental lines to an increasing CDDP concentration in the culture medium. In contrast, a six times repeated pulse exposure of 6.7 microM or 16.7 microM CDDP for 1 h did not result in a cell line that showed a higher survival in CDDP-containing medium. The ID50 value for CDDP was seven to eight times higher for the resistant lines and those lines were able to grow at 3.3 microM CDDP. The induced resistance was stable during at least 25 doubling times. The CDDP-resistant sublines showed cross-resistance to the CDDP-analogues cis-diammine-1,1-cyclobutane-dicarboxylateplatinum(II) and cis-dichlorobis(isopropylamine)-trans-dihydroxyplatinum(IV) indicating that resistance to the different platinum compounds is generated by a common mechanism. The resistant sublines were also cross-resistant to mitomycin C and melphalan. The degree of cross-resistance for the tested drugs varied widely between the two cell lines. Resistance to CDDP was clearly correlated to decreased amounts of platinum in the resistant cells as compared to the sensitive cells. The amplification and expression of genes encoding proteins that had been shown to be involved in multidrug resistance, e.g., the Mr 170,000 P-glycoprotein was also studied. No amplification or overexpression of these genes could be shown in the resistant cell lines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897238

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

Authors:  I Demirhan; O Hasselmayer; D Hofmann; A Chandra; F P Svinarchuk; V V Vlassov; J Engels; P Chandra
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

2.  Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?

Authors:  L A Yakubov; E A Deeva; V F Zarytova; E M Ivanova; A S Ryte; L V Yurchenko; V V Vlassov
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Probing the Mechanism of Action of Cry41Aa on HepG2 through the Establishment of a Resistant Subline.

Authors:  Wided Souissi; Tweedie Alistair; Barbara Domanska; Eva Fortea; Michelle J West; Jean-Louis Schwartz; Neil Crickmore
Journal:  Toxins (Basel)       Date:  2022-04-29       Impact factor: 5.075

4.  Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo.

Authors:  Hisataka Kitano; Yoh Masaoka; Atsushi Mamiya; Yusuke Fujiwara; Toshio Miki; Chiaki Hidai
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

5.  DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.

Authors:  Sham S Kakar; Christopher A Worth; Zhenglong Wang; Kelsey Carter; Mariusz Ratajczak; Pranesh Gunjal
Journal:  J Cancer Stem Cell Res       Date:  2016-04-19

6.  A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats.

Authors:  A Marinelli; C J van de Velde; P J Kuppen; H C Franken; J H Souverijn; A M Eggermont
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

7.  In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.

Authors:  K J Mellish; L R Kelland; K R Harrap
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

Review 8.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

9.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

10.  Formation of interaction products of carboplatin with DNA in vitro and in cancer patients.

Authors:  P M Terheggen; A C Begg; J Y Emondt; R Dubbelman; B G Floot; L den Engelse
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.